GlassScriptPhysician profile
Fonda Jiang
NPI 1043590649
$7,351.23
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,648 · 2020: $1,054 · 2021: $1,032 · 2022: $1,719 · 2023: $1,876 · 2024: $22.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,818 · Education: $80.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,817.71 |
| Education | $80.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,630.73 | 2019-2024 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,007.81 | 2019-2023 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $669.90 | 2019-2023 | Dupixent |
| Abbvie INC. | $470.97 | 2022-2023 | |
| Pfizer INC. | $447.44 | 2019-2023 | |
| Amgen INC. | $390.15 | 2021-2023 | Tezspire |
| Genzyme Corporation | $356.64 | 2019-2023 | |
| Pharming Healthcare, INC. | $345.66 | 2019-2022 | |
| Genentech USA, INC. | $297.57 | 2019-2023 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $278.60 | 2020-2023 | Hyqvia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.67 | 2019-2021 | |
| Optinose US, INC. | $185.19 | 2020-2023 | |
| Shire North American Group INC | $119.67 | 2019 | |
| Novartis Pharmaceuticals Corporation | $108.33 | 2019-2023 | |
| Kaleo, INC. | $95.55 | 2019-2023 | Auvi-Q |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $93.18 | 2020-2021 | |
| Leo Pharma INC. | $91.28 | 2022 | |
| Incyte Corporation | $82.49 | 2022-2023 | Opzelura |
| Grifols USA, LLC | $72.65 | 2020-2023 | Xembify |
| Biocryst US Sales Co., LLC | $65.69 | 2021-2022 | |
| Alk-Abello, INC | $63.79 | 2019-2022 | |
| Phadia US INC. | $33.88 | 2021 | |
| Aimmune Therapeutics, INC. | $29.99 | 2021-2022 | |
| Octapharma USA, INC. | $29.11 | 2020 | |
| Merck Sharp & Dohme LLC | $27.31 | 2023 | |
| Jubilant Hollisterstier LLC | $22.36 | 2020 | |
| Blueprint Medicines Corporation | $21.28 | 2023 | Ayvakit |
| Uswm, LLC | $20.00 | 2021 | |
| Biocryst Pharmaceuticals, INC. | $19.88 | 2020 | |
| Hikma Pharmaceuticals USA | $18.46 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fonda Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.